Reduced expression of Rho GDP dissociation inhibitor 2 mRNA is associated with lymph node metastasis in gastric carcinoma

Shida,Atsuo; Fujioka,Shuichi; Takahashi,Naoto; Aoki,Hiroaki; Okamoto,Tomoyoshi; Mitsumori,Norio; Omura,Nobuo; Yanaga,Katsuhiko

doi:10.3892/ol.2013.1379

Reduced expression of Rho GDP dissociation inhibitor 2 mRNA is associated with lymph node metastasis in gastric carcinoma

Authors:
- Atsuo Shida
- Shuichi Fujioka
- Naoto Takahashi
- Hiroaki Aoki
- Tomoyoshi Okamoto
- Norio Mitsumori
- Nobuo Omura
- Katsuhiko Yanaga
View Affiliations

Affiliations: Department of Surgery, Jikei University School of Medicine, Minato‑ku, Tokyo 105‑8461, Japan
Published online on: June 6, 2013 https://doi.org/10.3892/ol.2013.1379
Pages: 463-467

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Small GTPase proteins, including RhoA, RhoB, RhoC, Rac1 and cdc42, are molecules that have significant roles in linking cell shape and cell cycle progression in cytoskeletal arrangements and mitogenic signaling. Rho GDP dissociation inhibitor 2 (RhoGDI2) has recently been identified as a metastasis suppressor gene in models of bladder cancer. RhoGDI2 has also been identified as a potential regulator of tumorigenesis and cancer progression. The present study aimed to clarify the significance of RhoGDI2 gene expression in gastric carcinoma and to evaluate the outcome of affected patients. A total of 46 pairs of normal mucosa and cancer specimens were obtained from patients who had undergone a gastrectomy for primary gastric carcinoma and were subjected to semi‑quantitative reverse transcription polymerase chain reaction (RT‑PCR) for RhoGDI2. The expression of RhoGDI2 mRNA was significantly higher in early‑stage gastric cancer specimens compared with the normal gastric epithelium samples. By contrast, the depth of the tumor was negatively correlated with RhoGDI2 mRNA expression. In addition, a reduced expression of RhoGDI2 mRNA was associated with venous system invasion and lymph node metastasis. RhoGDI2 mRNA was more frequently expressed in differentiated adenocarcinoma compared with poorly‑differentiated adenocarcinoma. Although the statistical significance was not established, RhoGDI2‑positive patients tended to have a superior oncological outcome compared with RhoGDI2‑negative patients. The reduced expression of RhoGDI2 mRNA in gastric carcinoma is associated with venous system invasion and lymph node metastasis.

View Figures

View References

1.	Sahai E and Marshall CJ: RHO-GTPases and cancer. Nat Rev Cancer. 2:133–142. 2002. View Article : Google Scholar
2.	Clark EA, Golub TR, Lander ES and Hynes RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 406:532–535. 2000. View Article : Google Scholar : PubMed/NCBI
3.	Ueda T, Kikuchi A, Ohga N, Yamamoto J and Takai Y: Purification and characterization from bovine brain cytosol of a novel regulatory protein inhibiting the dissociation of GDP from and the subsequent binding of GTP to rhoB p20, a ras p21-like GTP-binding protein. J Biol Chem. 265:9373–9380. 1990.
4.	Leonard D, Hart MJ, Platko JV, et al: The identification and characterization of a GDP-dissociation inhibitor (GDI) for the CDC42Hs protein. J Biol Chem. 267:22860–22868. 1992.PubMed/NCBI
5.	Abo A, Pick E, Hall A, Totty N, Teahan CG and Segal AW: Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature. 353:668–670. 1991. View Article : Google Scholar : PubMed/NCBI
6.	Scherle P, Behrens T and Staudt LM: Ly-GDI, a GDP-dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes. Proc Natl Acad Sci USA. 90:7568–7572. 1993. View Article : Google Scholar : PubMed/NCBI
7.	Lelias JM, Adra CN, Wulf GM, et al: cDNA cloning of a human mRNA preferentially expressed in hematopoietic cells and with homology to a GDP-dissociation inhibitor for the rho GTP-binding proteins. Proc Natl Acad Sci USA. 90:1479–1483. 1993. View Article : Google Scholar : PubMed/NCBI
8.	Leffers H, Nielsen MS, Andersen AH, et al: Identification of two human Rho GDP dissociation inhibitor proteins whose over expression leads to disruption of the actin cytoskeleton. Exp Cell Res. 209:165–174. 1993. View Article : Google Scholar
9.	Seraj MJ, Harding MA, Gildea JJ, Welch DR and Theodorescu D: The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin Exp Metastasis. 18:519–525. 2000. View Article : Google Scholar : PubMed/NCBI
10.	Gildea JJ, Seraj MJ, Oxford G, et al: RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res. 62:6418–6423. 2002.PubMed/NCBI
11.	Gildea JJ, Golden WL, Harding MA and Theodorescu D: Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer. 27:252–263. 2000. View Article : Google Scholar : PubMed/NCBI
12.	Theodorescu D, Sapinoso LM, Conaway MR, et al: Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res. 10:3800–3806. 2004. View Article : Google Scholar : PubMed/NCBI
13.	Hu LD, Zou HF, Zhan SX and Cao KM: Biphasic expression of RhoGDI2 in the progression of breast cancer and its negative relation with lymph node metastasis. Oncol Rep. 17:1383–1389. 2007.PubMed/NCBI
14.	Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer. 1:10–24. 1998. View Article : Google Scholar : PubMed/NCBI
15.	Olofsson B: Rho guanine dissociation inhibitors: pivotal molecules in cellular signaling. Cell Signal. 11:545–554. 1999. View Article : Google Scholar : PubMed/NCBI
16.	Stevens EV, Banet N, Onesto C, et al: RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis. Small GTPases. 2:202–210. 2011. View Article : Google Scholar : PubMed/NCBI
17.	Tapper J, Kettunen E, El-Rifai W, et al: Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet. 128:1–6. 2001. View Article : Google Scholar : PubMed/NCBI
18.	Yanagawa T, Watanabe H, Takeuchi T, et al: Overexpression of autocrine motility factor in metastatic tumor cells: possible association with augmented expression of KIF3A and GDI-beta. Lab Invest. 84:513–522. 2004. View Article : Google Scholar : PubMed/NCBI
19.	Cho HJ, Baek KE, Park SM, et al: RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer. Clin Cancer Res. 15:2612–2619. 2009. View Article : Google Scholar : PubMed/NCBI
20.	Dransart E, Olofsson B and Cherfils J: RhoGDIs revisited: novel roles in Rho regulation. Traffic. 6:957–966. 2005. View Article : Google Scholar : PubMed/NCBI